17,261 trials
Nicotine Dependence · Smoking · Heavy Drinking
Primary: Number of Participants Reporting Continuous Smoking Abstinence in the Extended Varenicline Pretreatment Versus Short-term Varenicline Pretreatment Conditions. — 4; 2…
Epilepsy · Partial Onset Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days) — 5 participants
Myelodysplastic Syndrome · Aplastic Anemia
Primary: Overall Response — 8; 8; 4 participants
Endothelial Dysfunction
Primary: Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0 — 4.08; 2.77; 2.97; 2.66 % of preocclusion diameter
Atrial Fibrillation
Primary: Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by…
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) — 0 participants
Leukemia
Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants
Asthma
Primary: Emax: Maximum Value of FEV1 for Every Treatment Visits — 3.788; 3.784; 3.756; 3.763 Liters
Chronic Constipation
Primary: Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency — 2.59; 3.25; 3.57; 4.29 SBMs per week — p=0.0337
Parkinson Disease · Depression
Primary: Hamilton Depression Scale — 10.84; 12.45; 15.81 units on a scale
Nicotine Dependence
Primary: Weight Gain at 26 Weeks. — 6.75; 9.71 pounds
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Burkitt's Lymphoma · Lymphoblastic Lymphoma · Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose for Cyclophosphamide (MTD) — 200 mg/m^2
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects